Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMinneapolis Heart Institute Foundation
About this trial
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.
Eligibility criteria
Qualifiers
None
Disqualifiers
Concomitant PCI and TEER
Congenital heart disease
Stage D heart failure
Uncontrolled atrial fibrillation
Trial design
Treatments tested in this trial
- Cardiac MRI
Treatment groups
125 Participants
are divided into 1 treatment groupLocations
6Italy
IRCCS Ospedale San Raffaele20132, Milan Italy
United States
Minneapolis Heart Institute Foundation55407, MinneapolisMinnesota, United States
Sanger Heart and Vascular Institute28204, CharlotteNorth Carolina, United States
The Christ Hospital Health Network45219, CincinnatiOhio, United States
Sponsors and collaborators
Minneapolis Heart Institute Foundation
Lead sponsor
Source ClinicalTrials.gov